Moderna Presents mRESVIA and mRNA-1010 Revaccination Data at ESCMID Global Congress

At the ESCMID Global Congress in Munich (April 17–21, 2026), Moderna presented two late-breaking data sets relevant to mRNA vaccine revaccination in older adults. First, interim Phase 3 data on heterologous revaccination with mRESVIA (mRNA-1345 RSV vaccine) administered more than 12 months after a prior protein-based RSV vaccine in adults aged 60 and older showed the regimen was well-tolerated with no new safety concerns and robust immune responses, supporting annual or heterologous mRESVIA revaccination. Second, a post-hoc immunogenicity analysis from a study of mRNA-1010, the investigational quadrivalent mRNA influenza vaccine, in adults aged 50 and older demonstrated consistent immunogenicity across sequential flu vaccination cycles. The FDA PDUFA target date for the mRNA-1010 BLA (split into cohorts: 50–64 and 65+ years) remains August 5, 2026, after a February 2026 regulatory reversal in which FDA initially declined review before reversing course.